Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Repligen's ebitda for the twelve months ending Sep 30, 2026 was $96.14M, up 23.3% year over year. For fiscal 2025 it was $133.91M, up 287.5% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $275.66M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.91M | +287.5% |
| FY2024 | Dec 31, 2024 | $34.56M | -70.3% |
| FY2023 | Dec 31, 2023 | $116.26M | -57.8% |
| FY2022 | Dec 31, 2022 | $275.66M | +34.0% |
| FY2021 | Dec 31, 2021 | $205.70M | +112.3% |
| FY2020 | Dec 31, 2020 | $96.89M | +70.1% |
| FY2019 | Dec 31, 2019 | $56.95M | +36.4% |
| FY2018 | Dec 31, 2018 | $41.77M | +70.4% |
| FY2017 | Dec 31, 2017 | $24.51M | +15.0% |
| FY2016 | Dec 31, 2016 | $21.31M | +16.1% |
| FY2015 | Dec 31, 2015 | $18.36M | +24.8% |
| FY2014 | Dec 31, 2014 | $14.71M | -43.4% |
| FY2013 | Dec 31, 2013 | $25.99M | +1898.3% |
| FY2011 | Mar 31, 2011 | $1.30M | – |
| FY2010 | Mar 31, 2010 | -$4.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.42M | -128.3% |
| Q2 FY2026 | Jun 30, 2026 | $33.04M | -2.8% |
| Q1 FY2026 | Mar 31, 2026 | $35.70M | +41.2% |
| Q4 FY2025 | Dec 31, 2025 | $37.82M | – |
| Q3 FY2025 | Sep 30, 2025 | $36.83M | +284.1% |
| Q2 FY2025 | Jun 30, 2025 | $33.98M | +51.4% |
| Q1 FY2025 | Mar 31, 2025 | $25.28M | +22.4% |
| Q4 FY2024 | Dec 31, 2024 | -$18.13M | -166.8% |
| Q3 FY2024 | Sep 30, 2024 | $9.59M | -60.9% |
| Q2 FY2024 | Jun 30, 2024 | $22.44M | -36.6% |
| Q1 FY2024 | Mar 31, 2024 | $20.66M | -29.3% |
| Q4 FY2023 | Dec 31, 2023 | $27.13M | -57.1% |
| Q3 FY2023 | Sep 30, 2023 | $24.51M | -62.5% |
| Q2 FY2023 | Jun 30, 2023 | $35.38M | -53.0% |
| Q1 FY2023 | Mar 31, 2023 | $29.23M | -59.3% |
| Q4 FY2022 | Dec 31, 2022 | $63.22M | +30.5% |
| Q3 FY2022 | Sep 30, 2022 | $65.34M | +18.4% |
| Q2 FY2022 | Jun 30, 2022 | $75.27M | +31.5% |
| Q1 FY2022 | Mar 31, 2022 | $71.83M | +60.2% |
| Q4 FY2021 | Dec 31, 2021 | $48.45M | +94.5% |
| Q3 FY2021 | Sep 30, 2021 | $55.20M | +99.5% |
| Q2 FY2021 | Jun 30, 2021 | $57.22M | +119.9% |
| Q1 FY2021 | Mar 31, 2021 | $44.83M | +145.0% |
| Q4 FY2020 | Dec 31, 2020 | $24.91M | +108.0% |
| Q3 FY2020 | Sep 30, 2020 | $27.67M | +102.0% |
| Q2 FY2020 | Jun 30, 2020 | $26.02M | +63.7% |
| Q1 FY2020 | Mar 31, 2020 | $18.30M | +18.9% |
| Q4 FY2019 | Dec 31, 2019 | $11.97M | +1.0% |
| Q3 FY2019 | Sep 30, 2019 | $13.70M | +16.4% |
| Q2 FY2019 | Jun 30, 2019 | $15.89M | +93.7% |
| Q1 FY2019 | Mar 31, 2019 | $15.38M | +54.8% |
| Q4 FY2018 | Dec 31, 2018 | $11.86M | +60.3% |
| Q3 FY2018 | Sep 30, 2018 | $11.77M | +337.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.21M | +14.5% |
| Q1 FY2018 | Mar 31, 2018 | $9.94M | +36.9% |
| Q4 FY2017 | Dec 31, 2017 | $7.40M | +68.3% |
| Q3 FY2017 | Sep 30, 2017 | $2.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.17M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.40M | – |
See a number that looks wrong?